The application of the MEK inhibitor trametinib thus could attenuate PF‐induced ERK1/2 phosphorylation in DLD‐1 and HCT116 cells (Figure S7, Supporting Information), and we wondered whether the combination of PF (DKC1 inhibitor) and trametinib (MEK inhibitor) could synergistically suppress tumor growth. Here, MAP2K7 is linked to neoplasm.